Clinical trial
Ispinesib In Combination With Capecitabine In Patients With Solid Tumors
NCT00119171 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00119171 |
|---|---|
| Title | Ispinesib In Combination With Capecitabine In Patients With Solid Tumors |
| Official title | A Phase I, Open-Label, Dose-Escalation Study of the Safety and Tolerability of Ispinesib in Combination With Capecitabine on an Every 21-Day Schedule in Subjects With Advanced Solid Tumors |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Solid Tumor Cancer |
| Intervention type | Drug |
| Interventions | Ispinesib, Capecitabine |
| Enrollment | 30 |
| Start date | Nov 1, 2004 |
| First posted | Jul 13, 2005 |
| Last update posted | Oct 16, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: